Compass Therapeutics Inc.

Clinical-stage oncology company developing bispecific antibodies that target the tumor vasculature and immune checkpoints. Lead asset tovecimig (CTX-009), a DLL4 x VEGF-A bispecific, met its primary ORR endpoint in the Phase 2/3 COMPANION-002 study in second-line biliary tract cancer, with topline secondary endpoints (PFS, OS) reading out in 2026.